Company / Free Cash Flow
BioMarin Pharmaceutical Free Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
$725.0M
FY2025
5-year range
$54.9M / $725.0M
FY2021-FY2025
Trend
+48.7%
vs FY2024
Sector context
#20 of 194
Health Care
What the data says
Among 194 Health Care companies, BioMarin Pharmaceutical is in the top 10% for free cash flow. Free Cash Flow has increased for 3 consecutive years, from $55M in FY2022 to $725M in FY2025.
Based on SEC 10-K filings.
$725M in FY2025 with a 3-year CAGR of +136.3%. Top quartile in the Health Care sector.
Improved from $63M to $725M over the past 2 years.
Health Care sector context is included.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- +136.3%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 10% in Health CareTop 10% of 194This company $725.0M Sector average $470.6M
▼
+54.1% above sector average
Key checks
Key Insights
- BioMarin Pharmaceutical's free cash flow has grown for 3 consecutive years.
- 3-year CAGR of +136.3%, indicating consistent growth.
- In FY2025, free cash flow increased 48.7% year-over-year.
- Ranks #20 out of 194 companies in the Health Care sector.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $725.0M | +48.7% |
| FY2024 | $487.4M | +679.0% |
| FY2023 | $62.6M | +13.9% |
| FY2022 | $54.9M | -73.7% |
| FY2021 | $209.0M | +821.9% |
| FY2020 | -$28.9M | +70.1% |
| FY2019 | -$96.8M | +22.2% |
| FY2018 | -$124.4M | +40.2% |
| FY2017 | -$208.0M | +44.7% |
| FY2016 | -$376.2M | +15.9% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026